About Us
Transforming care for people living with Type 2 Diabetes.
Our story
Endogenex is a clinical stage company, that in partnership with Mayo Clinic, was founded to improve outcomes for people living with Type 2 Diabetes. Endogenex’s focus is on the principle that effective treatment for Type 2 Diabetes can extend beyond pharmacologic options and reset the disease process. Through development of the endoscopic ReCETTM Procedure and the novel application of non-thermal pulsed electric fields, Endogenex is striving to help people with Type 2 Diabetes regain control of their blood glucose levels.
Leadership team
Stacey Pugh
Lian Cunningham, MD
Lian brings 20+ years of clinical affairs and leadership experience to the Endogenex team. Her prior leadership roles include VP of clinical affairs at both BAROnova and TriReme Medical, Inc., and medical director/VP of clinical research and education at VNUSMedical Technologies (acquired by Covidien). Earlier in her career, Lian was an assistant professor at Loyola University of Chicago and a practicing vascular surgeon in Shanghai, China.
Brent Collins
Brent has more than 25 years of proven success bringing early-stage medical technologies from concept to global commercialization. He has served in leadership roles at Torax Medical (acquired by Johnson & Johnson), St. Jude Medical, ACIST Medical (acquired by Bracco Group) and Cascade Medical. He has a BS in business administration and marketing from University of St. Thomas.
Chris Sorli, MD, PhD
Dr. Sorli is an expert in the field of metabolic disorders including diabetes management. He has held leadership positions at Acerus Pharmaceutical and Sanofi where he led strategy and execution of all Medical Affairs activities across a broad product portfolio. Dr. Sorli is board certified in Endocrinology, Diabetes and Metabolism, and Internal Medicine and led The Center of Excellence in Diabetes and Metabolism, a clinical research center and metabolic surgery program in Billings, MT. He is a nationally and internationally recognized researcher and presenter on the topics of Type 2 Diabetes, Obesity, Metabolic Disease, and Metabolic Syndrome.
Melanie Hess
Melanie has over 20 years of medical industry experience specializing in regulatory strategy, compliance and global regulatory affairs. Prior to joining Endogenex, she held regulatory positions at Osprey Medical, American Medical Systems, Endo Pharmaceutical (AMS) and St. Jude Medical. Melanie spent 8 years as an intensive/critical care RN. She holds a BSN from the University of Minnesota and an MBA from the University of Phoenix.
Peter Sorensen
Peter has over a decade of experience in raising equity, debt control and accounting, supporting all areas of human resources, forecasting and finance. Prior to joining Endogenex, he held an accounting role for Liva Nova PLC and Caisson Interventional. He holds a BA in business administration from Bethel University and an MBA from St. Cloud State University.
Board of directors
Stacey Pugh
CEO
Endogenex
Learn about Stacey
Stacey is a leader in medical technology with 20 years of experience in medical device research, development and commercialization. Prior to joining the team, Stacey was the Chief Commercial Officer at Butterfly Network, leading planning, organization, sales and marketing. She has also held positions as President of Medtronic’s Neurovascular Operating unit and as Vice President of Global Medical Affairs and Clinical Affairs at Covidien’s Neurovascular Division. Stacey spent her early career in a variety of clinical development roles at Kinetic Concepts and began her career in critical care and trauma nursing, nursing education, and directed the human subject research program for Texas Tech University Health Sciences Centers.
Juliet Tammenoms Bakker
Co-founder and managing director
Longitude Capital
Learn about Juliet
Juliet is co-founder of Longitude Capital, a healthcare venture capital firm. Prior to Longitude Capital, she served as managing director of Pequot Ventures where she founded the life sciences investment practice. Juliet currently serves on the boards of Endogenex, Inc.; Nalu Medical, Inc.; and Ceribell, Inc. Past board experience includes Eargo, Inc. (Nasdaq: EAR); Axonics Modulation Technologies (Nasdaq: AXNX); Insulet (Nasdaq: PODD); and Venus Concept (Nasdaq: VERO).
Juliet serves as a member of the Advisory Council for the College of Agriculture and Life Sciences at Cornell University and the Advisory Board of the Boys and Girls Club of Greenwich. She holds an MPA from the Harvard Kennedy School and a BS from the College of Agriculture and Life Sciences at Cornell University.
James Eadie
Managing director
Santé Ventures
Learn about James
James has been with Santé Ventures since 2010. Prior, he was the medical director and vice chair of emergency medicine at Wilford Hall Medical Center, an academic level-one trauma center in San Antonio.
James served in the Air Force completing two tours in Iraq as a critical care transport team chief and as the emergency department commander. He separated honorably as a Major in 2008. James has an MBA from the University of Texas McCombs School Of Business, his MD from Harvard Medical School, and a BS in bioengineering, Summa Cum Laude, from the University of Michigan. He is board-certified in emergency medicine and completed his residency at Massachusetts General Hospital and Brigham and Women’s Hospital.
John Deedrick
President
CHIP Solutions
Learn about John
John is an experienced senior executive and an early-stage company founder, director and advisor. His career encompasses venture investments in over 50 companies, a board director for more than 35 companies, a co-founder role in 22 companies. John is president of CHIP Solutions, a business consulting firm and serves on the boards of ActivOrtho, CHIP II, Endogenex, FourMation Medical, SubioMed and CERTENTE. John holds a BS in business administration from Northwestern University of St. Paul and an MBA from St. Thomas University.
Gerry Brunk
Managing Director
Lumira Ventures
Learn about Gerry
Gerry Brunk is a co-founder and Managing Director of Lumira Ventures, a healthcare venture capital firm. He has led investments in biotechnology and medical device companies including MAKO Surgical, Pharmasset, HistoSonics, Endotronix, Cadence Neuroscience and Bardy Diagnostics. Prior to beginning his investing career Gerry was a founder of several venture capital-funded healthcare companies, served in the healthcare practice at Boston Consulting Group and was a member of the investment banking group at Credit Suisse First Boston. He holds an MBA from Stanford University Graduate School of Business and a BA from the University of Virginia.
Jeff Terrell
General Partner
Hatteras Venture Partners
Learn about Jeff
Jeff is a General Partner at Hatteras Venture Partners. His MedTech career started with Medtronic selling spinal implants and image-guided surgery equipment. Prior to this role, Jeff spent two years pursuing a childhood dream to be a professional quarterback, spending time with the Kansas City Chiefs and Dallas Cowboys. Jeff joined Hatteras during business school, working with one of the firm’s medical device portfolio companies in a corporate and business development role. Once that investment sold, and after graduating from business school, Jeff joined the Hatteras investment team full-time. Since then, he has assisted in overall firm operations, deal flow activities and diligence across a wide variety of investment opportunities.
Jeff currently co-leads Hatteras’ medical device practice. He serves as a director on the boards of AtaCor Medical, Boomerang Medical, Cardiosense, Endogenex, 410 Medical, and Dropworks (acquired by Bio-Rad Laboratories). He also serves as a board observer at Contego Medical, Rapid Pulse, Avivomed, and Qvella. He holds a bachelor’s degree from Princeton University, and an MBA from Duke University, with a focus on healthcare and finance.
Our investors
Endogenex is supported by leading venture capital and healthcare investors experienced in the development of technologies to treat complex healthcare problems.